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Abstract
Objective Stereotactic body radiation therapy (SBRT) is an
attractive option for prostate cancer due to its short treatment
duration and cost. In this report, we compare the efficacy and
toxicity outcomes of prostate cancer patients treated with
SBRT to those who received intensity-modulated radiation
therapy (IMRT).
Methods Two hundred sixty-three patients with localized
prostate adenocarcinoma were included, ranging from clini-
cally very low- to high-risk groups. We retrospectively com-
pare consecutive patients treated with SBRTwith consecutive
patients treated with conventionally fractionated IMRT. For
most patients, SBRT was delivered to a total dose of
36.25 Gy in five fractions and IMRT to 75.6 Gy in 42 frac-
tions. To minimize selection bias, we perform propensity
score analyses.
Results The treatment groups became similar after propensity
matching with absolute standard bias reduced to ≤0.19. For
the first analysis, 5-year actuarial survival was 90.8 and
88.1 % in SBRT and IMRT groups, respectively
(p = 0.7260), while FFBF was 88.7 and 95.5 %, respectively
(p = 0.1720). For the second analysis (accounting for risk
group), actuarial 5-year survival was 96.7 and 87.1 % in the
SBRT and IMRT groups, respectively (p = 0.3025), while
FFBF was 89.7 and 90.3 %, respectively (p = 0.6446). Toxic-
ity did not exceed grade 3 in any of the studied patients. The
highest recorded genitourinary toxicity at the time of latest
follow-up was grade 2.
Conclusion Our data support the hypothesis that SBRT has
non-inferior efficacy and toxicity rates as IMRT. Given the
lower cost and convenience for patients, SBRT may be con-
sidered as an alternative treatment for localized prostate
cancer.
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Introduction
Intensity-modulated radiation therapy (IMRT) is one of the
standard radiotherapeutic techniques for the definitive treat-
ment of localized prostate cancer. There are several decades of
data supporting excellent biochemical control and overall sur-
vival for delivery of conventionally fractionated radiation
therapy to the prostate and surrounding tissue at risk, while
maintaining acceptable toxicity [1]. IMRT was adopted prior
to long-term data from phase 3 trials and demonstrated a su-
perior therapeutic ratio [2–4]. The rationale was based on
IMRT being a technical innovation on an already proven
Our data support the hypothesis that stereotactic body radiation therapy is
non-inferior to intensity-modulated radiation therapy for the primary
treatment of localized prostate cancer. Given the lower cost and conve-
nience for patients, stereotactic body radiation therapy could be consid-
ered for localized prostate cancer.
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treatment modality, conventionally fractionated radiation ther-
apy, delivered by three-dimensional conformal radiation ther-
apy (3DCRT) or two-dimensional conventional techniques
(2DCT) with sufficient long-term data to support its use as
standard of care.
Stereotactic body radiation therapy (SBRT) is a technolog-
ically advanced treatment modality that takes advantage of the
low alpha-beta ratio of prostate cancer in order to deliver ex-
treme hypofractionated radiation therapy. As a result, SBRT
achieves high biological equivalent doses substantially above
those attempted in IMRT.
There has been further interest in SBRT for prostate cancer
due to its convenience for patients (duration of 1 to 2 weeks, as
compared to 8 to 9 weeks of IMRT) and lower cost [5]. SBRT
has been considered a different treatment modality than con-
ventionally fractionated therapy and IMRT due to the complex
radiobiological differences of extreme hypofractionation com-
pared to standard fractionation. Late responding normal tissue
surrounding the malignant tissue may be more susceptible to
late toxicity after receiving high doses delivered in fewer frac-
tions. Therefore, one may argue that extreme hypofractionated
schemes require many years of follow-up to accurately assess
late toxicity.
It is ideal to adopt a new therapeutic modality that is
cheaper and more convenient for patients once randomized
trials demonstrate non-inferior outcomes and acceptable tox-
icity. However, by the time phase 3 trial data mature in local-
ized prostate cancer, we may be faced with new scientific and
bureaucratic pressures that push prostate cancer treatment in a
different direction. Reliance on randomized trials alone is not
practical, given the past difficulty in enrolling patients into
phase 3 trials that compare prostate cancer treatment modali-
ties head-to-head. The logic used to adopt IMRT as standard
of care bymeans of long-term data from 3DCRT/2DCTcan be
similarly applied to SBRT, by using data from high-dose rate
(HDR) monotherapy as a surrogate, in which data supporting
the latter [6–11] justify use of the former.
Therefore, a balance is required which allows new tech-
nologies to be offered to patients prior to maturation of
long-term data from phase 3 trials. This can be achieved
for prostate SBRT through evidenced-based treatment pro-
tocols based on long-term data from HDR monotherapy
and 5-year data from phase 2 trials of SBRT. Irrespective
of the controversy surrounding SBRT, there have been ear-
ly publications which report promising clinical efficacy of
SBRT for localized prostate cancer, along with low rates of
toxicity [12]. However, the literature is limited by short-/
intermediate-term follow-up. As we await long-term data
from ongoing randomized studies, there has been a high
level of interest to compare extreme hypofractionation to
conventionally fractionated approaches.
We seek to enhance the perspective on this topic by com-
paring our experience with SBRT and IMRT. Yu et al.
published an analysis of Medicare beneficiaries comparing
toxicity and cost between SBRT and IMRT.
At 2-year follow-up, they demonstrated a small but statis-
tically significant increase in toxicity in patients who received
SBRT as compared to IMRT, while the former had a substan-
tially lower financial cost [5]. Our current study similarly
compares SBRT toxicity to IMRT, but additionally analyzes
treatment outcome by means of biochemical control and over-
all survival utilizing propensity score modeling.
Methods
Stereotactic body radiation therapy
All 142 consecutive men with localized prostate cancer
treated between 2007 through 2012 at our satellite radia-
tion oncology center with SBRT as monotherapy were in-
cluded in this IRB-approved study. The CyberKnife system
with multi-plan inverse treatment planning and motion
tracking of internal fiducials was used. Treatment planning
began with fiducial placement into the prostate. A CT scan
was obtained 10–14 days later. T2 fast echo MRI was ob-
tained and three-dimensionally registered by fiducials to
the CT in the majority of patients.
The clinical target volume (CTV) was the prostate for
low-risk patients and the prostate plus proximal seminal ves-
icle base for most intermediate- and high-risk patients. Pelvic
lymph nodes were never targeted with SBRT. Five fractions
were prescribed to the planning target volume (PTV) that
consisted of the CTV with a 5-mm margin in all directions
except 3 mm posteriorly. The dose delivered changed over the
time of the study. Initially, patients received 35 Gy, followed
by 37.5 Gy, and at the time of this publication to 36.25 Gy,
driven by data available at that time and standard protocol
established by Accuray. At least 95 % of the PTV received
the prescribed dose normalized to the 75–85 % isodose line
(dose heterogeneity 17–33 %). Less than 1 cm3 of rectum
received 36 Gy, 50 % of the prescribed dose could not cross
the posterior rectal wall, and <10 cm3 of bladder received
37 Gy. The average CTV and PTV were 56.9 cm3 (std
dev 27.7 cm3) and 98.0 cm3 (std dev 48.9 cm3), respective-
ly. Orthogonal 120-kV x-ray image pairs were obtained
throughout treatment for use in motion tracking. Real-time
prostate position was locked on by the relative fiducial posi-
tion on the x-rays. For those patients with evenly distributed
fiducials in the prostate quadrants, the prostate’s rotation was
also tracked and corrections were made in real time.
Intensity-modulated radiation therapy
All 121 consecutive men with localized prostate cancer be-
tween 2007 through 2012 at our hospital radiation oncology
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center treated with IMRTwere included in this IRB-approved
study. Of note, IMRT and SBRT are delivered at separate
geographic sites within the same radiation oncology depart-
ment/hospital. The CTV was defined as the prostate with
8-mm margin in all directions except 5 mm posteriorly in
low-risk patients, prostate plus seminal vesicles with 5- to
8-mm margin for intermediate-risk patients, and prostate plus
seminal vesicles plus true pelvic lymph nodes with 5- to 8-mm
margin for high-risk patients. Dose constraints to the rectum
were defined as V65 <17% andV40 <35%, while the bladder
constraint was V65 <25 % and V40 <50 %. All patients were
simulated in the supine position with immobilization, full
bladder, and empty rectum. CT and MRI treatment plan-
ning was completed with merging of the images for
contouring of the prostate. Image guidance was provided
by BAT ultrasound pretreatment daily and patients were
treated with full bladder daily. Usually, five to seven
isocentric beams were utilized to treat the prostate with
6 MV photons optimized with an inverse optimization al-
gorithm with at least 95 % of the prostate receiving the
prescribed dose. The majority of patients received at least
75.6 Gy to the prostate in 1.8 Gy per fraction. Of those that
received less than 75.6 Gy, the majority were stratified into
either the very-low-risk or low-risk groups.
Analysis
PSA nadir to date is defined as the lowest PSAvalue following
radiotherapy. Benign PSA bounce was defined as a PSA rise
of ≥0.2 ng/mL above its previous nadir with subsequent de-
cline to that nadir or lower. Biochemical failure (BF) was
assessed using the nadir +2 (Phoenix) definition. Toxicity
was assessed using the Radiation Therapy Oncology Group
(RTOG) criteria; acute toxicity occurred within 3 months and
late toxicity >3 months following treatment. Risk group was
based on the National Cancer Center Network (NCCN) ver-
sion 2.2014 classification: very low, low, favorable intermedi-
ate (one intermediate risk factor), unfavorable intermediate
(more than one intermediate risk factor), and high. Since there
were few very high risk patients, they were included in the
high-risk group.
Statistics
The overall sample is described using measures of central
tendency (mean andmedian) and variation [standard deviation
and interquartile range (IQR)], and compared by treatment
group using two-sample t tests and Fisher exact tests, as ap-
propriate. To minimize selection bias inherent in treatment
group allocation, propensity score modeling was used to
match the two groups using a logistic regression approach
[13]. To evaluate the robustness of the choice of matching
covariates, two sets of characteristics were used for the pro-
pensity score modeling: (1) individual patient and tumor char-
acteristics including age, tumor stage, Gleason score, pretreat-
ment PSA, treatment year, and androgen deprivation therapy
(ADT) use; and (2) NCCN version 2.2014 risk group, age,
treatment year, and ADT use. For each set of matching covar-
iates, various propensity score modeling strategies were
employed, including simple 1:1, 1:1 with replacement, 1:1
with caliper, 1:1 optimal, full matching, and sub-classification.
The methods were compared in terms of bias reduction using
box plots (Fig. 1) and overlap of the propensity scores using
box plots. An absolute standard bias measure <0.20 is
a b
Fig. 1 Box plots of different matching approaches: a matched on multiple covariates, b matched on risk groups
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considered small, and sufficient overlap is required for the
propensity scores [14]. As seen in Fig. 1, the method dem-
onstrating optimal bias reduction was 1:1 with caliper for
both sets of matching covariates, and was thus chosen as
the basis for outcome analysis. Figure 2 demonstrates that
bias was reduced to <0.20 for all variables used in both of
the matching analyses. Kaplan-Meier estimates of overall
survival and freedom from biochemical failure were used
to describe the patients overall, and comparisons were ac-
complished using log-rank statistics [15, 16].
Results
Patient and treatment characteristics
The outcomes of 263 patients were analyzed, with median
follow-up of 43 months (IQR 24–58). The SBRT treatment
group of 142 consecutively treated patients had median
follow-up of 34 months (IQR 22–54). The IMRT treatment
group of 121 consecutively treated patients had median
follow-up of 51 months (IQR 33–64). SBRT doses were
35.0 Gy in five fractions (4 %), 36.25 Gy in five fractions
(75 %), and 37.5 Gy in five fractions (21 %) of patients. IMRT
was delivered in conventional fractionation with 1.8–2.0 Gy
per fraction, median dose 75.6 Gy delivered in 42 fractions,
specifically, 6 % 79.2 Gy, 18 % 78 Gy, 59 % 75.6 Gy, and
17 % 72 Gy.
The SBRT group comprised patients with younger age and
lower risk disease determined by the pooled results of a
two-sample t test and Fisher’s exact test, respectively, as com-
pared to the IMRT group (Table 1).
Patients treated with IMRTwere more than twice as likely
to receive ADT compared with SBRT, which was consistent
for each risk group.
Unmatched outcome
At most recent follow-up, there were no deaths from prostate
cancer in either treatment group. All patients died of causes
unrelated to malignancy in the SBRT group, whereas 9 of 15
patients in the IMRT group died of cancer-related causes not
associated with prostate adenocarcinoma—primaries of the
lung, pancreas, esophagus, and leukemia. Metastatic pro-
gression occurred after biochemical failure in three of six
patients in the SBRT group and three of nine patients in the
IMRT group.
Treatment with both modalities was well tolerated.
Acute and late genitourinary (GU) toxicity experienced
after treatment did not exceed grade 3. The most severe
acute and late gastrointestinal (GI) toxicity was grade 2.
All grade 3 toxicities subsided at most recent follow-up.
Grade 2 GU toxicity persisted in 12 and 14 % of patients in
the IMRT and SBRT groups, respectively. Grade 2 GI tox-
icity persisted in 1 and 3 % of IMRT and SBRT groups,
respectively.
Grade 3 erectile dysfunction (ED) was defined as inabil-
ity to achieve an erection sufficient for intercourse despite
the use of medications or the need for penile prosthesis.
The analysis of this particular outcome excluded patients
on long-term ADT and those who had grade 3 ED at base-
line. At most recent follow-up, grade 3 ED persisted in
17 % of those who received IMRT and in 6 % of those
who received SBRT.
a b
Fig. 2 Graphs of unmatched and matched absolute standard bias: aMatched on multiple covariates, b matched on risk groups
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Matched analyses
In order to minimize selection bias resulting from confound-
ing patient and treatment differences between the SBRT and
IMRT treatment groups, we performed two additional propen-
sity score analyses which matched patients between the two
groups. The first analysis relied on 1:1 propensity score
matching with a caliper using age, Gleason score, pretreat-
ment PSA, treatment year, tumor stage, and ADT use. The
resulting treatment groups became similar, with the absolute
standard bias reduced to ≤0.19 for all covariates (Table 2). For
this sample, the 5-year actuarial survival (Table 3 and Fig. 3)
was 90.8 and 88.1% in the SBRTand IMRT treatment groups,
respectively (p = 0.7260, overall comparison between curves).
For the same sample, the 5-year actuarial FFBF was 88.7 and
95.5 % in the SBRT and IMRT treatment groups, respectively
(p = 0.1720 overall, Table 3 and Fig. 3).
Similarly, we generated a propensity score analysis using
1:1 matching with a caliper to account for differences in
NCCN version 2.2014 risk group, ADT use, age, and treat-
ment year. As a result of the matching, the resulting treatment
groups again became similar, for which the absolute standard
bias was reduced to ≤0.19 for all risk groups (Table 2). For this
sample, the 5-year actuarial of overall survival (Table 3 and
Fig. 3) was 96.7 and 87.1 % in the SBRTand IMRT treatment
groups, respectively (p = 0.3025, overall comparison between
curves). For the same sample, the 5-year actuarial of FFBF
was 89.7 and 90.3% in the SBRTand IMRT treatment groups,
respectively (p = 0.6446 overall, Table 3 and Fig. 3).
Discussion
Given the retrospective observational nature of our study, two
separate matching methods were used to reduce bias intro-
duced by confounding prognostic factors with treatment, and
thus balance differences between treatment groups. Results
from 1:1 propensity score matching with caliper based on
age, Gleason score, pretreatment PSA, treatment year, tumor
stage, and ADT use demonstrate no statistically significant
differences in outcomes between SBRT and IMRT treatment
groups. Consistent with these findings, similar matching
based on NCCN risk group, ADT use, age, and treatment year
also demonstrate no statistically significant differences in out-
comes between treatment groups. Ideally, propensity score
matching seeks to minimize differences between imbalanced
groups in order to create samples similar to those in a prospec-
tive randomized study. Thus, separate analyses produced sim-
ilar results, in which there was no difference in overall survival
or FFBF in our patient population.
A common critique of SBRT for prostate cancer is that
adopting it as routine practice should await long-term results
from randomized phase 3 trials. It has been suggested that an
ongoing Swedish phase 3 trial of hypofractionated radiother-
apy delivered in >5 fractions (ISRCTN45905321) [17] will
help shed light on this topic once published [18]. Several
phase 3 trials of hypofractionation in >5 fractions have been
reported, albeit using moderate hypofractionation, of which
four of five show no significant difference in rates of late
toxicity [19–23]. The trial with the longest follow-up
(90 months) demonstrated that a conventionally fractionated
scheme was an independent prognostic factor for worse late
GU toxicity [21].
Several prospective studies of SBRT have reported high
rates of biochemical control with acceptable toxicity. King et
al. demonstrate the favorable therapeutic ratio in a consortium
of patients from phase 2 trials who were treated between 2003
and 2011 at eight institutions. Five-year bRFSwas achieved in
Table 1 Patient and tumor characteristics for unmatched data
SBRT IMRT p value
Sample size (n) 142 121
Age (years) <0.0001
Mean (std dev) 66.9 (8.0) 71.6 (6.7)
Median (IQR) 67 (61, 73) 72 (67, 77)
Gleason score, n (%) <0.0001
5,6 76 (53.5 %) 34 (28.1 %)
7 54 (38.0 %) 61 (50.4 %)
8,9,10 12 (8.5 %) 26 (21.5 %)
Pre-treatment PSA (ng/mL) 0.0907
Mean (std dev) 8.1(7.7) 11.0 (18.8)
Median (IQR) 5.7 (4.4, 8.3) 6.2 (5.0, 9.5)
NCCN risk group n (%) <0.0001
Very low 28 (19.7 %) 9 (7.4 %)
Low 33 (23.2 %) 13 (10.7 %)
Favorable Intermediate 50 (35.2 %) 39 (32.2 %)
Unfavorable intermediate 13 (9.2 %) 28 (23.1 %)
High 18 (12.7 %) 32 (26.5 %)
ADTuse n (%) 40 (28.2 %) 87 (71.9 %) <0.0001
Treatment year n (%) 0.0007
2007 12 (8.5 %) 28 (23.1 %)
2008 36 (25.4 %) 32 (26.5 %)
2009 25 (17.6 %) 25 (20.7 %)
2010 24 (16.9 %) 19 (15.7 %)
2011 29 (20.4 %) 7 (5.8 %)
2012 16 (11.3 %) 10 (8.3 %)
Tumor stage n (%) 0.0001
T1b, T1c, T2a, T2b 132 (93 %) 91 (75.8 %)
T2c, T3, T3a 10 (7 %) 29 (24.2 %)
*Age and pretreatment PSA p values computed using the pooled p value
of two-sample t tests. Gleason score, NCCN risk group, ADT use, treat-
ment year, and tumor stage p values computed using Fisher’s exact test
(two-sided p value for ADT use and tumor stage)
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5, 6 0.2810 0.5352 0.3867 0.36
7 0.5041 0.3803 0.44 0.4933
8, 9, 10 0.2149 0.0845 0.1733 0.1467
Pretreatment PSA 10.9962 8.0702 0.1559 10.9892 8.3375 0.1413
EOT year
2007 0.2314 0.0845 0.3469 0.2267 0.1467 0.1889 0.1351 0.1622 0.0683
2008 0.2645 0.2535 0.0247 0.2667 0.2667 0 0.3108 0.2703 0.0915
2009 0.2066 0.1761 0.0752 0.2 0.1867 0.0328 0.2027 0.1757 0.0665
2010 0.157 0.169 0.0328 0.1333 0.16 0.073 0.2027 0.2027 0
2011 0.0579 0.2042 0.6244 0.0933 0.12 0.1137 0.0811 0.1216 0.1729
2012 0.0826 0.1127 0.1086 0.08 0.12 0.1447 0.0676 0.0676 0
Tumor stage 0.3636 0.1205
T1b, T1c, T2a, T2b 0.7583 0.9296 0.80 0.88
T2c, T3, T3a 0.2417 0.0704 0.1867 0.12
ADTuse 0.719 0.2817 0.9689 0.56 0.5333 0.0591 0.5676 0.527 0.0898
5 risk groups
High 0.2645 0.1268 0.3109 0.2162 0.1892 0.061
Unfavorable
intermediate
0.2314 0.0915 0.3303 0.1351 0.1351 0
Favorable
intermediate
* * * * * *
Low 0.1074 0.2324 0.4018 0.1622 0.1757 0.0435
Very low 0.0744 0.1972 0.4661 0.1081 0.1081 0
*Reference group
Table 3 Unmatched and 1:1 caliper matching with 5-year actuarial survival
1 2 3 4 5 Log-rank
p value
Overall survival All patients unmatched All patients (N = 263) 98.8 % 97.5 % 94.2 % 92.5 % 89.6 %
Matched using all
covariates
SBRT (N = 75) 100 % 98.4 % 94.4 % 94.4 % 90.8 % 0.7260
IMRT (N = 75) 96.0 % 94.6 % 91.1 % 91.1 % 88.1 %
Matched using risk group SBRT (N = 74) 100.0 % 98.5 % 96.7 % 96.7 % 96.7 % 0.3025
IMRT (N = 74) 97.3 % 95.8 % 90.4 % 90.4 % 87.1 %
Freedom from biochemical
failure
All patients unmatched All patients (N = 263) 99.6 % 97.3 % 96.1 % 93.8 % 91.7 %
Matched using all
covariates
SBRT (N = 75) 100 % 93.1 % 93.1 % 93.1 % 88.7 % 0.1720
IMRT (N = 75) 98.6 % 98.6 % 98.6 % 98.6 % 95.5 %
Matched using risk group SBRT (N = 74) 100.0 % 93.4 % 93.4 % 93.4 % 89.7 % 0.6446
IMRT (N = 74) 100.0 % 100.0 % 98.0 % 93.7 % 90.3 %
*Matched using all covariates: SBRT and IMRT treatment groups matched by treatment year, t-stage, age, GS, pretreatment PSA, ADT use
*Matched using risk group: SBRT and IMRT treatment groups matched by NCCN v2.2014 risk group, ADT use, age, treatment year
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95, 84, and 81% of low-, intermediate-, and high-risk patients,
respectively. The use of ADT and SBRT dose did not signif-
icantly affect bRFS even after stratifying by risk group [12]. In
a separate publication, King et al. describe patient-reported
quality of life (QOL) from a sample of 864 patients from four
phase 2 studies that evaluate SBRT. They demonstrated uri-
nary and bowel QOL decline within the first 3 months after
treatment, recovering by 6months, remaining stable at 3 years’
follow-up, and subsequently achieving superior QOL as com-
pared to baseline [24]. This trend was independent of severity
of acute toxicity and duration of ADT use. Katz et al. com-
pared similar prospective QOL measures in patients who re-
ceived SBRT and radical prostatectomy. Both modalities re-
sulted in decline of urinary and bowel QOL at 1 month, with
an upward trend at later time points. After SBRT, QOL recov-
ered by 6 months to levels not significantly different than
baseline (latest 36 months), whereas QOL after surgery
remained significantly lower compared to baseline at all time
points [25]. Katz et al. series of 477 patients with low- and
intermediate-risk prostate cancer treated with SBRT demon-
strated a 7-year actuarial FFBF of 95.6 and 89.6 % for low-
and intermediate-risk patients, respectively. No late grade 3 GI
toxicity was noted and late GU toxicity was limited to 1.7 %
[26].
Comparison of SBRT to IMRT for localized prostate can-
cer has been published in one other study to date [5]. An
analysis of Medicare beneficiaries in the United States (age
>65) treated from 2008 through 2011 showed greater toxicity
associated with SBRT than with IMRT. The absolute differ-
ence in toxicity at the latest time point of 24 months was 8 %
(p = 0.01). However, toxicity was neither graded nor reported
subjectively. The radiation treatment platform used for SBRT
Fig. 3 Five-year actuarial survival and freedom from biochemical failure: a1, a2 matched on multiple covariates; b1, b2 matched on risk groups
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was not reported nor was there a dose/volume analysis pre-
sented. It was reported based on claims submitted via interna-
tional coding of disease (ICD-9). Differences in toxicity may
have little clinical relevance if, for example, an 8 % difference
comprised mostly of grade 1 or 2 toxicity. Furthermore, late
toxicity will be inherently missed in a study which does not
exceed 24months’ follow-up. TheMedicare analysis does not
report PSA outcome or survival, as this information is not
obtainable through the Medicare database. Nonetheless, Yu
et al. provide an important perspective on two distinct treat-
ment modalities. The financial cost was reported to be sub-
stantially lower for SBRT than IMRT, with mean cost for a full
course of IMRT $7348 more than SBRT.
Our current series complements the Medicare analysis by
Yu et al. Together, our publications enable a hypothesis to be
generated for future prospective trials, in which SBRT may be
non-inferior to IMRT in regard to GU/GI toxicity, survival,
and biochemical outcome, while having a substantially lower
financial cost. Limitations of our study include the selection
bias that arises in retrospective observational series. However,
we attempt to minimize such bias by incorporating two statis-
tical propensity-matched analyses.
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